H.C. Wainwright Reiterates Buy Rating on Monte Rosa Therapeutics (GLUE)

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $25.00 price target on Monte Rosa Therapeutics (NASDAQ: GLUE).

The analyst commented: "MRT-8102 cleared our lower-dose bar, supporting the gout and HS programs that contribute ~$15 of our $25 price target. Monte Rosa’s October 1 GFORCE-1 update reported median high sensitivity C-reactive protein (hsCRP) reductions of 86%, 79%, and 85% at 5mg, 20mg, and 40mg daily, respectively, after four weeks in a 108-participant randomized study. The 5mg result exceeded our preferred ~80-85% suppression benchmark, with no AE-related discontinuations at that dose. This supports testing lower doses in longer patient studies without an apparent sacrifice in the measured pharmacology. Gout and hidradenitis suppurativa (HS) remain our larger valuation drivers, with cardiovascular development carrying a 15% probability of approval and a later Phase 2b start in 1H27. We make no changes to our estimates, valuation, or probability of approval. The next clinical data catalyst is the MRT-2359 plus enza update by YE26, followed by initial MRT-8102 gout data expected in 2H27. We reiterate our Buy rating and 12-month price target of $25 per share."

For an analyst ratings summary and ratings history on Monte Rosa Therapeutics click here. For more ratings news on Monte Rosa Therapeutics click here.

Shares of Monte Rosa Therapeutics closed at $10.50 yesterday.

You May Also Be Interested In

• Citi cuts investment banking analyst program to two years - Bloomberg
• Bernstein SocGen on Linde (LIN): 'Linde has the capability to ramp up its space business very quickly'
• Truist Securities on Tesla (TSLA): 'We view AI developments as far more important than auto deliveries'